Clinical trials: Zoledronic acid, completed
Hormone-Refractory Prostate Cancer
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
The objective of MER-101-03 is to examine the effects of two different dosing regimens of MER-101 20mg tablets versus Zometa 4mg IV infusion once-monthly therapy.
- Trial name
- NCT00636740
- Testing
- Zoledronic Acid 20mg Tablets, Zoledronic Acid
- Where
- 13 sites in United States, Estonia and 1 more
- Volunteers
- 30 people
- Sponsor
- Merrion Pharmaceuticals, LLC
Prostatic Neoplasms, Bone Density
Study on Evaluation of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
The purpose of this study is to assess the effect of zoledronic acid on bone mineral density in prostatic cancer patients currently receiving androgen deprivation therapy.
- Trial name
- NCT00489905
- Testing
- Zolderonic acid (Zometa)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hospital Authority, Hong Kong
Osteoporosis, Osteopenia
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
The purpose of this study is to apply a novel advanced magnetic resonance imaging methodology to evaluate the response to drug intervention involving two treatment arms of postmenopausal participants with osteoporosis, randomized…
- Trial name
- TERIZOL (NCT01153425)
- Testing
- Virtual Bone Biopsy, Teriparatide, Zoledronic Acid
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pennsylvania
Paget's Disease of Bone
Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period
The core study looked at the effect of Zoledronic Acid given once as an intravenous (i.v.) infusion compared to 60 days of oral Risedronate in patients with Paget's disease of bone.
- Trial name
- NCT00051636
- Testing
- Zoledronic Acid, Risedronate, Calcium and Vitamin D
- Where
- 34 sites in United States, Australia and 4 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
The purpose of this study is to study the MRD status after VELCADE based induction therapy (VELCADE, lenalidomide, dexamethasone or VELCADE, liposomal doxorubicin, dexamethasone) in patients with previously untreated multiple…
- Trial name
- NCT01215344
- Testing
- VELCADE, Lenalidomide, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Sarcopenia, Osteoporosis
Muscle Impact of Treating Osteoporosis
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity).
- Trial name
- MITO (NCT05666310)
- Testing
- Denosumab, Zoledronic Acid
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nami Safai Haeri
Prostate Cancer
The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
The purpose of this study is to compare the effect of an investigational drug used intravenously and placebo administered every three months for one year, on bone loss associated with initial androgen deprivation) in men with…
- Trial name
- NCT00063609
- Testing
- zoledronic acid
- Where
- 44 sites in United States
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)
The purpose of this research is to establish if a once a year dose of Zoledronic Acid is sufficient to suppress and maintain urine and serum bone density markers (NTx) and serum CTx within normal range at 12 months post-dosing in…
- Trial name
- CTIBL (NCT00712985)
- Testing
- Zometa
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Nasopharyngeal Cancer
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
The purpose of this study is to assess the efficacy of addition of zometa to anti-neoplastic treatment compared with anti-neoplastic treatment alone, as measured by the primary efficacy variable of SREs (Skeletal Related Events)…
- Trial name
- NCT00697619
- Testing
- Zometa (zoledronic acid)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Osteoporosis, Postmenopausal
MAGnesium Effect With ANtiosteoporotic Drugs
Randomized pilot clinical trial to demonstrate superiority of bisphosphonate-magnesium combination over bisphosphonates alone in postmenopausal osteoporosis in slowing bone remodeling as assessed by C-terminal telopeptide of bone…
- Trial name
- MAGELLAN (NCT05328154)
- Testing
- Follow-up of patients with postmenopausal osteoporosis, with or without fractures, requiring initiation of injectable bisphosphonate therapy as part of their usual care, Follow-up of patients with postmenopausal osteoporosis, fractured or not, requiring initiation of injectable bisphosphonate therapy as part of care with magnesium supplementation
- Where
- France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Clermont-Ferrand
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
This randomized phase III trial studies two different schedules of zoledronic acid to compare how well they work in reducing bone-related complications in patients with breast cancer, prostate cancer, or multiple myeloma that has…
- Conditions
- Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone
- Trial name
- NCT00869206
- Testing
- zoledronic acid
- Where
- 504 sites in United States, Puerto Rico
- Volunteers
- 1,822 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Prostate Cancer
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
RATIONALE: Zoledronate may prevent bone loss in patients with prostate cancer undergoing radiation therapy and hormone therapy. It is not yet known whether zoledronate is more effective than calcium and vitamin D alone in…
- Trial name
- NCT00329797
- Testing
- Calcium, Zoledronic acid, radiation therapy
- Where
- 88 sites in United States, Canada
- Volunteers
- 109 people
- Sponsor
- Radiation Therapy Oncology Group
Multiple Myeloma
Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates
The purpose of this research study is to define the time a molecule in the participants bones called NTX begins to rise after receiving treatment with bisphosphonates.
- Trial name
- NCT00577642
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Massachusetts General Hospital
Renal Insufficiency
Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
- Trial name
- NCT00580047
- Testing
- Zoledronic Acid, Calcium with vitamin D, Alendronate
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Nebraska
Multiple Myeloma
A Multiple Myeloma Trial in Patients With Bone Metastases
The purpose of this trial is to study the safety of treating patients with multiple myeloma and at least one bone lesion with zoledronic acid 4mg intravenously (IV) every 3 - 4 weeks for 2 years.
- Trial name
- NCT00104104
- Testing
- zoledronic acid
- Where
- 68 sites in United States
- Volunteers
- 179 people
- Sponsor
- Novartis Pharmaceuticals
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Osteoporosis
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
The aim of this study was to examine the effect of zoledronic acid and alendronate on bone metabolism as measured by biomarkers in postmenopausal women with osteoporosis.
- Trial name
- ROSE (NCT00404820)
- Testing
- Zoledronic acid 5 mg solution, Alendronate 70 mg tablets, Calcium/Vitamin D
- Where
- Germany
- Volunteers
- 604 people
- Sponsor
- Novartis
Bone Metastases
A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone metastases in subjects with advanced breast cancer.
- Trial name
- NCT00321464
- Testing
- Denosumab, Zoledronic Acid
- Volunteers
- 2,049 people
- Sponsor
- Amgen
Prostate Cancer, Adenocarcinoma of the Prostate
Atrasentan and Zometa for Men With Prostate Cancer Metastatic to Bone
The main purpose of this study is to look at the effects (good or bad) that Atrasentan given alone and Atrasentan given with Zometa has on levels of bone formation and bone destruction in men with prostate cancer that has spread…
- Trial name
- NCT00181558
- Testing
- Atrasentan, Zoledronic Acid (Zometa)
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Massachusetts General Hospital